proe-PRAN-oh-lole

Therapeutic Classification: antianginals, antiarrhythmics (Class II), antihypertensives, vascular headache suppressants

Pharmacologic Classification: beta blockers

• Hypertension, angina, arrhythmias, hypertrophic cardiomyopathy, thyrotoxicosis, essential tremors, pheochromocytoma (all but Hemangeol).
• Prevention and management of MI, and the prevention of vascular headaches (all but Hemangeol).
• Proliferating infantile hemangioma requiring systemic therapy (Hemangeol only)

Unlabeled Uses:

• Also used to manage alcohol withdrawal, aggressive behavior, antipsychotic-associated akathisia, situational anxiety, and esophageal varices.
• Post-traumatic stress disorder (PTSD).

• Blocks stimulation of beta₁(myocardial) and beta₂ (pulmonary, vascular, and uterine)-adrenergic receptor sites; its mechanism for the treatment of infantile hemangiomas is unknown.

• Decreased heart rate and BP.
• Suppression of arrhythmias.
• Prevention of MI.
• Prevention of vascular headaches.
• Hemangioma resolution

Absorption: Well absorbed but undergoes extensive first-pass hepatic metabolism.

Distribution: Moderate CNS penetration. Crosses the placenta; enters breast milk.

Protein Binding: 93%.

Metabolism/Excretion: Almost completely metabolized by the liver (primarily for CYP2D6 isoenzyme) (the CYP2D6 enzyme system exhibits genetic polymorphism; 7% of population may be poor metabolizers and may have significantly ↑ propranolol concentrations and an ↑ risk of adverse effects).

Half-life: 3.4–6 hr.

(cardiovascular effects)

†Following single dose, full effect not seen until several wk of therapy.

Contraindicated in:

• Hypersensitivity
• Uncompensated HF
• Pulmonary edema
• Cardiogenic shock
• Bradycardia, sick sinus syndrome, or heart block (unless pacemaker present)
• Premature infants with corrected age <5 wk (Hemangeol only)
• Asthma or history of bronchospasm (Hemangeol only)
• BP <50/30 mmHg (Hemangeol only)
• Pheochromocytoma (Hemangeol only)
• Pedi: Infants <2 kg (Hemangeol only).

Use Cautiously in:

• Renal or hepatic impairment
• Pulmonary disease (including asthma)
• Diabetes mellitus (may mask signs of hypoglycemia)
• Thyrotoxicosis (may mask symptoms)
• History of severe allergic reactions (may ↑ intensity of response)
• Skeletal muscle disease (may exacerbate myopathy)
• OB: Crosses the placenta and may cause fetal/neonatal bradycardia, hypotension, hypoglycemia, or respiratory depression. May also ↓ blood supply to the placenta, ↑ the risk for premature birth or fetal death, and cause intrauterine growth retardation. May ↑ risk of cardiac and pulmonary complications in the infant during the neonatal time frame. Lactation: Safety not established in breastfeeding
• Pedi: ↑risk of hypoglycemia in children, especially during periods of fasting such as before surgery, during prolonged exertion, or with coexisting renal insufficiency
• Geri: Older adults may have ↑ sensitivity to beta blockers; initial dose reduction and careful titration recommended.

CV: ARRHYTHMIAS, BRADYCARDIA, HF, orthostatic hypotension, peripheral vasoconstriction, PULMONARY EDEMA.

Derm: ERYTHEMA MULTIFORME, EXFOLIATIVE DERMATITIS, itching, rash, STEVENS-JOHNSON SYNDROME (SJS), TOXIC EPIDERMAL NECROLYSIS.

EENT: blurred vision, dry eyes, nasal stuffiness.

Endo: hyperglycemia, hypoglycemia (↑ in children).

GI: constipation, diarrhea, nausea.

GU: erectile dysfunction, ↓ libido.

MS: arthralgia, back pain, muscle cramps, myopathy.

Neuro: fatigue, weakness, anxiety, depression, dizziness, drowsiness, insomnia, memory loss, mental status changes, nervousness, nightmares, paresthesia.

Resp: bronchospasm, wheezing.
Misc: drug-induced lupus syndrome, (INCLUDING ANAPHYLAXIS)HYPERSENSITIVITY REACTIONS .

Drug-Drug:

• General anesthesia, IV phenytoin, and verapamil may cause additive myocardial depression.
• Additive bradycardia may occur with digoxin.
• Additive hypotension may occur with other antihypertensives, acute ingestion of alcohol, or nitrates.
• Levels may be ↓ with chronic alcohol use.
• Concurrent use with amphetamines, cocaine, ephedrine, epinephrine, norepinephrine, phenylephrine, or pseudoephedrine may result in unopposed alpha-adrenergic stimulation (excessive hypertension, bradycardia).
• Concurrent thyroid administration may ↓ effectiveness.
• May alter the effectiveness of insulin or oral hypoglycemics (dose adjustments may be necessary).
• May ↓ effectiveness of beta-adrenergic bronchodilators and theophylline.
• May ↓ beneficial beta cardiovascular effects of dopamine or dobutamine.
• Use cautiously within 14 days of MAO inhibitor therapy (may result in hypertension).
• Cimetidine may ↑ blood levels and toxicity.
• Concurrent NSAIDs may ↓ antihypertensive action.
• Smoking↑ metabolism and ↓ effects; smoking cessation may ↑ effects.
• May ↑ levels of lidocaine and bupivacaine.

• PO (Adults): Antianginal: 80–320 mg/day in 2–4 divided doses or once daily as extended/sustained-release capsules. Antihypertensive: 40 mg twice daily initially; may be ↑ as needed (usual range 120–240 mg/day; doses up to 1 g/day have been used); or 80 mg once daily as extended/sustained-release capsules, ↑ as needed up to 120 mg. InnoPran XL dosing form is designed to be given once daily at bedtime. Antiarrhythmic: 10–30 mg 3–4 times daily. Prevention of MI: 180–240 mg/day in divided doses. Hypertrophic cardiomyopathy: 20–40 mg 3–4 times daily. Adjunct therapy of pheochromocytoma: 20 mg 3 times daily to 40 mg 3–4 times daily concurrently with alpha-blocking therapy, started 3 days before surgery is planned. Vascular headache prevention: 20 mg 4 times daily or 80 mg/day as extended/sustained-release capsules; may be ↑ as needed up to 240 mg/day. Management of tremor: 40 mg twice daily; may be ↑ up to 120 mg/day (up to 320 mg have been used).
• PO (Children): Antihypertensive/antiarrhythmic: 0.5–1 mg/kg/day in 2–4 divided doses; may be ↑ as needed (usual range for maintenance dose is 2–4 mg/kg/day in 2 divided doses).
• PO (Children 5 wk–5 mo): Infantile hemangioma: 0.6 mg/kg twice daily (at least 9 hr apart); after 1 wk, ↑ to 1.1 mg/kg twice daily; after another wk, ↑ to 1.7 mg/kg twice daily and maintain for 6 mo.
• IV (Adults): Antiarrhythmic: 1–3 mg; may be repeated after 2 min and again in 4 hr if needed.
• IV (Children): Antiarrhythmic: 10–100 mcg (0.01–0.1 mg)/kg (up to 1 mg/dose); may be repeated every 6–8 hr if needed.

(Generic available)

• Immediate-release tablets: 10 mg; 20 mg; 40 mg; 60 mg; 80 mg;
• Extended-release capsules: 60 mg; 80 mg; 120 mg; 160 mg;
• Oral solution: 20 mg/5 mL; 40 mg/5 mL;
• Oral solution (Hemangeol): 4.28 mg/mL;
• Solution for injection: 1 mg/mL;
• In combination with: hydrochlorothiazide (generic only).

• Monitor BP and pulse frequently during dose adjustment period and periodically during therapy.
  • Abrupt withdrawal of propranolol may precipitate life-threatening arrhythmias, hypertension, or myocardial ischemia. Drug should be tapered over a 2-wk period before discontinuation. Assess patient carefully during tapering and after medication is discontinued. Consider that patients taking propranolol for non-cardiac indications may have undiagnosed cardiac disease. Abrupt discontinuation or withdrawal over too-short a period of time (less than 9 days) should be avoided.
  • Pedi: Assess pediatric patients for signs and symptoms of hypoglycemia, particularly when oral foods and fluids are restricted.
  • Patients receiving propranolol IV must have continuous ECG monitoring and may have pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) monitoring during and for several hrs after administration.
• Assess for orthostatic hypotension when assisting patient up from supine position.
• Monitor intake and output ratios and daily weight. Assess patient routinely for evidence of fluid overload (peripheral edema, dyspnea, rales/crackles, fatigue, weight gain, jugular venous distention).
• Assess for rash periodically during therapy. May cause SJS. Discontinue therapy if severe or if accompanied with fever, general malaise, fatigue, muscle or joint aches, blisters, oral lesions, conjunctivitis, hepatitis and/or eosinophilia.
• Angina: Assess frequency and characteristics of anginal attacks periodically during therapy.
• Vascular Headache Prophylaxis: Assess frequency, severity, characteristics, and location of vascular headaches periodically during therapy.
• PTSD: Assess frequency of symptoms (flashbacks, nightmares, efforts to avoid thoughts or activities that may trigger memories of the trauma, and hypervigilance) periodically during therapy.
• Infantile Hemangioma: Monitor heart rate and BP for 2 hr after propranolol initiation or dose increases. May worsen bradycardia or hypotension. Discontinue if symptomatic bradycardia (<80 beats per min) or hypotension (systolic BP <50 mmHg) occurs.

• May cause ↑ BUN, serum lipoprotein, potassium, triglyceride, and uric acid levels.
  • May cause ↑ ANA titers.
  • May cause ↓ or ↑ in blood glucose levels. In labile diabetic patients, hypoglycemia may be accompanied by precipitous ↑ of BP.

• Monitor patients receiving beta blockers for signs of overdose (bradycardia, severe dizziness or fainting, severe drowsiness, dyspnea, bluish fingernails or palms, seizures). Notify health care professional immediately if these signs occur.
  • Hypotension may be treated with modified Trendelenburg position and IV fluids unless contraindicated. Vasopressors (epinephrine, norepinephrine, dopamine, dobutamine) may also be used. Hypotension does not respond to beta agonists.
  • Glucagon has been used to treat bradycardia and hypotension.

• High Alert:IV vasoactive medications are inherently dangerous. Before administering intravenously, have second practitioner independently check the original order, dose calculations, and infusion pump settings. Also, patient harm or fatalities have occurred when switching from oral to IV propranolol; oral and parenteral doses are not interchangeable. IV dose is 1/10 of the oral dose. Change to oral therapy as soon as possible.
• High Alert:Do not confuse Inderal with Adderall.
• PO: Take apical pulse prior to administering. If <50 bpm or if arrhythmia occurs, hold medication and notify health care professional.
  • Administer with meals or directly after eating to enhance absorption.
  • DNC: Swallow extended release tablets whole; do not crush, break, or chew.Propranolol tablets may be crushed and mixed with food.
  • Administer Innopran XL tablets at bedtime and take consistently either on an empty stomach for with food. Avoid discontinuing abruptly, especially in patients with ischemic heart disease. Gradually decrease dose over 1–2 wk. If angina markedly worsens or acute coronary insufficiency develops, promptly resume therapy, at least temporarily and take other measures for management of unstable angina.
  • Mix propranolol oral solution with liquid or semisolid food (water, juices, applesauce, puddings). To ensure entire dose is taken, rinse glass with more liquid or have patient consume all of the applesauce or pudding. Do not store after mixing.
  • Administer Hemangeol during or right after a feeding to prevent hypoglycemia. Skip dose if child is not eating or is vomiting. Administer using oral syringe provided; if necessary may be diluted in small amount of milk or fruit juice and given in baby’s bottle.

IV Administration:

• Administer undiluted or dilute each 1 mg in 10 mL of D5W for injection.Undiluted: 1 mg/mL. Diluted in 10 mL of D5W: 0.1 mg/mL.
• Rate: Administer at 0.5 mg/min for adults to avoid hypotension and cardiac arrest; do not exceed 1 mg/min. Pedi: Administer over 10 min.
• Intermittent Infusion: May be diluted in 50 mL of 0.9% NaCl, D5W, D5/0.45% NaCl, D5/0.9% NaCl, or LR.Depends on dose.
• Rate: Infuse over 10–15 min.
• Y-Site Compatibility:
  • acyclovir
  • alemtuzumab
  • alteplase
  • amikacin
  • aminocaproic acid
  • aminophylline
  • amiodarone
  • anidulafungin
  • argatroban
  • arsenic trioxide
  • ascorbic acid
  • atropine
  • azathioprine
  • aztreonam
  • benztropine
  • bivalirudin
  • bleomycin
  • bumetanide
  • buprenorphine
  • butorphanol
  • calcium chloride
  • calcium gluconate
  • carboplatin
  • carmustine
  • caspofungin
  • cefazolin
  • cefotaxime
  • cefotetan
  • cefoxitin
  • ceftazidime
  • ceftriaxone
  • cefuroxime
  • chloramphenicol
  • chlorpromazine
  • cisplatin
  • clindamycin
  • cyanocobalamin
  • cyclophosphamide
  • cyclosporine
  • cytarabine
  • dacarbazine
  • dactinomycin
  • daptomycin
  • daunorubicin hydrochloride
  • dexamethasone
  • dexmedetomidine
  • dexrazoxane
  • digoxin
  • diltiazem
  • diphenhydramine
  • dobutamine
  • docetaxel
  • dopamine
  • doxorubicin hydrochloride
  • doxorubicin liposomal
  • doxycycline
  • enalaprilat
  • ephedrine
  • epinephrine
  • epirubicin
  • epoetin alfa
  • eptifibatide
  • ertapenem
  • erythromycin
  • esmolol
  • etoposide
  • etoposide phosphate
  • famotidine
  • fentanyl
  • fluconazole
  • fludarabine
  • fluorouracil
  • folic acid
  • foscarnet
  • fosphenytoin
  • furosemide
  • ganciclovir
  • gemcitabine
  • gemtuzumab ozogamicin
  • gentamicin
  • glycopyrrolate
  • granisetron
  • heparin
  • hetastarch
  • hydrocortisone
  • hydromorphone
  • idarubicin
  • ifosfamide
  • imipenem/cilastatin
  • irinotecan
  • isoproterenol
  • ketorolac
  • labetalol
  • LR
  • leucovorin calcium
  • levofloxacin
  • lidocaine
  • linezolid
  • lorazepam
  • magnesium sulfate
  • mannitol
  • meperidine
  • meropenem
  • mesna
  • methadone
  • methohexital
  • methotrexate
  • methylprednisolone
  • metoclopramide
  • metoprolol
  • metronidazole
  • midazolam
  • milrinone
  • mitoxantrone
  • morphine
  • moxifloxacin
  • multivitamins
  • mycophenolate
  • nafcillin
  • nalbuphine
  • naloxone
  • nicardipine
  • nitroglycerin
  • nitroprusside
  • norepinephrine
  • octreotide
  • ondansetron
  • oxacillin
  • oxaliplatin
  • oxytocin
  • palonosetron
  • pamidronate
  • papaverine
  • pemetrexed
  • penicillin G
  • pentamidine
  • pentobarbital
  • phenobarbital
  • phentolamine
  • phenylephrine
  • phytonadione
  • potassium acetate
  • potassium chloride
  • procainamide
  • prochlorperazine
  • promethazine
  • propofol
  • protamine
  • pyridoxine
  • rocuronium
  • sodium acetate
  • sodium bicarbonate
  • succinylcholine
  • sufentanil
  • tacrolimus
  • theophylline
  • thiamine
  • thiotepa
  • tigecycline
  • tirofiban
  • tobramycin
  • topotecan
  • vancomycin
  • vasopressin
  • vecuronium
  • verapamil
  • vinblastine
  • vincristine
  • vinorelbine
  • voriconazole
  • zoledronic acid
• Y-Site Incompatibility:
  • amphotericin B deoxycholate
  • amphotericin B lipid complex
  • amphotericin B liposomal
  • dantrolene
  • diazepam
  • indomethacin
  • insulin regular
  • mitomycin
  • paclitaxel
  • pantoprazole
  • phenytoin
  • piperacillin/tazobactam
  • trimethoprim/sulfamethoxazole
.

• Instruct patient to take medication as directed, at the same time each day, even if feeling well; do not skip or double up on missed doses. Take missed doses as soon as possible up to 4 hr before next dose (8 hr with extended-release propranolol). Inform patient that abrupt withdrawal can cause life-threatening arrhythmias, hypertension, or myocardial ischemia. Advise parent to read medication guide prior to starting and with each Rx refill in case of changes in Hemangeol.
• Advise patient to make sure enough medication is available for weekends, holidays, and vacations. A written prescription may be kept in wallet in case of emergency.
• Teach patient and family how to check pulse daily and BP biweekly. Advise patient to hold dose and contact health care professional if pulse is <50 bpm or BP changes significantly.
• May cause drowsiness or dizziness. Caution patients to avoid driving or other activities that require alertness until response to the drug is known.
• Advise patients to change positions slowly to minimize orthostatic hypotension, especially during initiation of therapy or when dose is increased.
• Caution patient that this medication may increase sensitivity to cold.
• Instruct patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking other Rx, OTC, or herbal products, especially NSAIDs and cold preparations, concurrently with this medication.
• Advise diabetic patients to closely monitor blood sugar, especially if weakness, malaise, irritability, or fatigue occurs. Medication may mask some signs of hypoglycemia, but dizziness and sweating may still occur. Acute hypertension may occur following insulin-induced hypoglycemia in patients receiving propranolol. Instruct parents/caregivers of children receiving Hemangeol how to recognize signs of hypoglycemia, and to notify health care professional and take child to nearest emergency department if hypoglycemia is suspected.
• Advise patient to notify health care professional if slow pulse, difficulty breathing, wheezing, cold hands and feet, dizziness, light-headedness, confusion, depression, rash, fever, sore throat, unusual bleeding, or bruising occurs.
• Instruct patient to inform health care professional of medication regimen prior to treatment or surgery.
• Advise females of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding. Monitor neonates exposed to propranolol during pregnancy for bradycardia, hypotension, hypoglycemia, and respiratory depression. May also ↓ blood supply to placenta, ↑ risk for premature birth or fetal death, and cause intrauterine growth retardation. May ↑ risk of cardiac and pulmonary complications in the infant during the neonatal time frame.
• Advise patient to carry identification describing disease process and medication regimen at all times.
• Hypertension: Reinforce the need to continue additional therapies for hypertension (weight loss, sodium restriction, stress reduction, regular exercise, moderation of alcohol consumption, and smoking cessation). Medication controls but does not cure hypertension.
• Angina: Caution patient to avoid overexertion with decrease in chest pain.
• Vascular Headache Prophylaxis: Caution patient that sharing this medication may be dangerous.
• PTSD: Advise patient that medication may relieve distressing symptoms but that psychotherapy is the primary treatment for the disorder. Refer patient and family to a PTSD support group.

• Decrease in BP.
• Control of arrhythmias without appearance of detrimental side effects.
• Reduction in frequency of anginal attacks.
• Increase in activity tolerance.
• Prevention of MI.
• Prevention of vascular headaches.
• Management of thyrotoxicosis.
• Management of pheochromocytoma.
• Decrease in tremors.
• Management of hypertrophic cardiomyopathy.
• Decrease in symptoms associated with PTSD.
• Resolution of infantile hemangioma (Hemangeol only)

Hemangeol, Inderal, Inderal LA, Inderal XL, InnoPran XL